Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

10.41
-0.1350-1.28%
Pre-market: 10.40-0.0050-0.05%06:33 EDT
Volume:2.41M
Turnover:25.65M
Market Cap:864.44M
PE:-12.01
High:11.25
Open:10.61
Low:10.39
Close:10.54
52wk High:15.10
52wk Low:1.99
Shares:83.08M
Float Shares:59.28M
Volume Ratio:1.07
T/O Rate:4.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8667
EPS(LYR):-0.8930
ROE:-34.18%
ROA:-20.52%
PB:3.78
PE(LYR):-11.65

Loading ...

Immix Biopharma Closes $125 Million Stock Offering

MT Newswires Live
·
13 hours ago

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

THOMSON REUTERS
·
13 hours ago

US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB

Reuters
·
Yesterday

Immix Biopharma, Inc. : Needham Raises Target Price to $30

THOMSON REUTERS
·
Yesterday

Immix Biopharma is Maintained at Buy by Needham

Dow Jones
·
Yesterday

Immix Biopharma price target raised to $30 from $27 at BofA

TIPRANKS
·
Sep 29

Immix Biopharma prices 11.36M share registered offering at $11.00

TIPRANKS
·
Sep 29

Immix Biopharma Prices 11,363,637-Share Offering at USD 11.00 Per Share for USD 125 Million Gross Proceeds

Reuters
·
Sep 29

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

THOMSON REUTERS
·
Sep 29

Immix Biopharma, - Prices 11,363,637 Shares at $11 Per Share

THOMSON REUTERS
·
Sep 29

Immix Biopharma, - Net Proceeds to Fund Nxc-201 Development, Working Capital, Corporate Purposes

THOMSON REUTERS
·
Sep 29

Immix Biopharma Says Nexicart-2 Interim Data Show 89% Complete Response Rate for NXC-201 in Relapsed/refractory AL Amyloidosis

Reuters
·
Sep 29

Immix Biopharma, - Nexicart-2 Final Readout and Bla Submission Planned for Mid-2027

THOMSON REUTERS
·
Sep 29

Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All Nexicart-2 Patients, with Mrd-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory Al Amyloidosis

THOMSON REUTERS
·
Sep 29

Immix Biopharma, - 100% of New Nexicart-2 Patients in Complete Response or Mrd-Negative

THOMSON REUTERS
·
Sep 29

Immix Biopharma, Inc. : Mizuho Raises Target Price to $26 from $15

THOMSON REUTERS
·
Sep 16

U.S. Research Roundup-Domino's, McDonald's, Starbucks

Reuters
·
Sep 16

Immix Biopharma is Maintained at Outperform by Mizuho

Dow Jones
·
Sep 15

Mizuho Raises Price Target on Immix Biopharma to $26 From $15, Keeps Outperform Rating

MT Newswires Live
·
Sep 15

Immix Biopharma Highlights NXC-201 CAR-T Data in Relapsed/refractory AL Amyloidosis Trial Presentation

Reuters
·
Sep 03